10x Genomics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| TXG | PACB | LAB | BIO | CTKB | ALMR | |
|---|---|---|---|---|---|---|
| Market cap | 8.80B | 792.62M | 243.14M | 10.16B | 764.30M | 1.90B |
| P/E (TTM) | — | — | — | 48.2 | — | — |
| Forward P/E | 880.7 | -6.1 | -61.6 | 39.0 | 84.0 | -65.9 |
| Price/book | 10.7 | 141.7 | 0.4 | 1.4 | 2.2 | 6.2 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +383.99% | +27.08% | −46.49% | +20.93% | +48.63% | +37.36% |
| Today | +3.42% | +4.51% | +0.85% | +1.35% | −1.34% | −9.36% |
The closest companies by business and industry (Medical Devices). Prices may be delayed up to 15 min.
Latest news
All TXG news ›Twist Bioscience Soars 12%, 10x Genomics Up 12% as Genomics Stocks Rebound
max-kegfire from Getty Images via Canva Twist Bioscience (TWST) stock jumped 12% today, and 10x Genomics (TXG) rose 12% right alongside it. Neither company had news to explain the move. Twist’s only release was the launch of a new…
10x Genomics Sinks 12%, Twist Down 15%, PacBio Down 10% as Genomics Stocks Give Back Rebound
freedomz and Artsanova from Getty Images via Canva 10x Genomics (TXG) sank 12% today, and the rest of the genomics tools group went with it: Twist Bioscience (TWST) fell 15% and Absci (ABSI) 12%. PacBio (PACB) dropped 10% ahead of its…
Sentira Brings Claude's AI to 10x Genomics’ Chromium Platform
By Julianna LeMieux, PhD Credit: 2253444748 / Moment / Getty Images But now, with advances in LLMs, researchers can use tools to answer questions without needing to be bioinformaticians. Today, 10x is launching Sentira Single Cell, a…
10x Genomics: Atera Takes Off, But Valuation Flies Too High
Atera (announced in April 2026) potentially augments 10x’s existing spatial biology offering by integrating whole-transcriptome coverage, subcellular-level spatial resolution, single-cell sensitivity, ... - I rate 10x Genomics a SELL with…
iSpecimen (NASDAQ:ISPC) and 10x Genomics (NASDAQ:TXG) Financial Review
Posted by Michael Walen on Oct 28th, 2026 10x Genomics (NASDAQ:TXG – Get Free Report) and iSpecimen (NASDAQ:ISPC – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses…
10x Genomics (NASDAQ:TXG) Given Equal Weight Rating at Stephens
Posted by Michael Walen on Oct 23rd, 2026 10x Genomics (NASDAQ:TXG – Get Free Report)‘s stock had its “equal weight” rating restated by equities research analysts at Stephens in a research report issued to clients and investors on Friday,…
10X Genomics Announces New Collaboration to Advance Single Cell and Spatial Applications Across Solid Tumors and Blood Cancers
10x Genomics, Inc. announced a multi-project research collaboration with Fred Hutchinson Cancer Center , one of the nation's leading cancer research institutions, to advance the use of single cell and... announced a multi-project research…
10x Genomics Drops Parse Suit After Patents Affirmed Invalid
Bloomberg Law News 10x Genomics Inc. will drop its lawsuit accusing Parse Biosciences Inc. of infringing cell-analysis technology after the Federal Circuit affirmed three asserted patents are invalid. The parties said in a Wednesday letter
Deutsche Bank Adjusts 10x Genomics Price Target to $70 From $40, Maintains Hold Rating
10x Genomics has an average rating of overweight and mean price target of $52.13, according to analysts polled by FactSet. ... Medical Equipment, Supplies & Distribution Deutsche Bank Adjusts 10x Genomics Price Target to $70 From $40,…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com6
- themarketsdaily.com4
- tikr.com2
- defenseworld.net1
- gurufocus.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 21 articles, not a forecast.